On Friday, Quince Therapeutics Inc (NASDAQ: QNCX) was 3.90% up from the session before settling in for the closing price of $1.54. A 52-week range for QNCX has been $0.66 – $2.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 7.53% over the past five years. When this article was written, the company’s average yearly earnings per share was at 17.56%. With a float of $41.11 million, this company’s outstanding shares have now reached $53.62 million.
Quince Therapeutics Inc (QNCX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Quince Therapeutics Inc stocks. The insider ownership of Quince Therapeutics Inc is 23.46%, while institutional ownership is 13.76%.
Quince Therapeutics Inc (QNCX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.13 earnings per share (EPS) during the time that was less than consensus figure (set at -0.1) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.93% during the next five years compared to 7.53% growth over the previous five years of trading.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
You can see what Quince Therapeutics Inc (QNCX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Quince Therapeutics Inc (QNCX)
Quince Therapeutics Inc (NASDAQ: QNCX) saw its 5-day average volume 0.13 million, a negative change from its year-to-date volume of 0.23 million. As of the previous 9 days, the stock’s Stochastic %D was 24.87%.
During the past 100 days, Quince Therapeutics Inc’s (QNCX) raw stochastic average was set at 66.16%, which indicates a significant increase from 27.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1120 in the past 14 days, which was lower than the 0.1124 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6630, while its 200-day Moving Average is $1.5084. Nevertheless, the first resistance level for the watch stands at $1.6561 in the near term. At $1.7122, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8044. If the price goes on to break the first support level at $1.5078, it is likely to go to the next support level at $1.4156. Assuming the price breaks the second support level, the third support level stands at $1.3595.
Quince Therapeutics Inc (NASDAQ: QNCX) Key Stats
There are 53,714K outstanding shares of the company, which has a market capitalization of 85.94 million. As of now, sales total 0 K while income totals -56,830 K. Its latest quarter income was 0 K while its last quarter net income were -16,050 K.
